Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04166487
Title Plasma-Adapted First-Line Pembro In NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Brigham and Women's Hospital Recruiting Boston Massachusetts 02115 United States Details
Dana Farber Cancer Institute Recruiting Boston Massachusetts 02115 United States Details
Boston Medical Center Recruiting Boston Massachusetts 02118 United States Details
Dana-Farber at Steward St. Elizabeth's Medical Center Recruiting Brighton Massachusetts 02135 United States Details
Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in clinical affiliation with South Shore Hospital Recruiting South Weymouth Massachusetts 02190 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field